To evaluate the therapeutic and financial benefits of protocol therapy for acute asthma using standard medications.
This study employed a sequential design in which the influence of an asthma care path on hospital admissions, length of stay (LOS) in the emergency department, and return visits were evaluated for 1 year.
This information was contrasted with similar data obtained from the 8 months immediately before the protocol was implemented (preprotocol) and a 12-month period after strict adherence to it had declined (admixture).
In all, 526 acute exacerbations of asthma were treated with the care path, and 429 and 558 episodes were evaluated during the preprotocol and admixture periods, respectively.
There were no significant differences between the presenting clinical or physiologic features of any group.
With the protocol, 77% of the patients resolved their symptoms within 1 : 47 ± 0.02 hours : minutes of arrival in the emergency department with a 2% return rate within 24 hours.
The algorithms used quickly identified those needing hospitalization.
Patients not meeting the criteria for discharge after receiving the treatments employed typically did not resolve their symptoms for days (average hospital stay 4.1 ± 0.2 days).
Compared with the preprotocol period, the care path significantly reduced the LOS by 50 minutes, the number of urgent and intensive care unit admissions by 27% and 41%, respectively, and ...
Mots-clés Pascal : Asthme, Protocole thérapeutique, Chimiothérapie, Evaluation, Coût, Etats Unis, Amérique du Nord, Amérique, Etude comparative, Traitement, Homme, Appareil respiratoire pathologie, Bronchopneumopathie obstructive
Mots-clés Pascal anglais : Asthma, Therapeutic protocol, Chemotherapy, Evaluation, Costs, United States, North America, America, Comparative study, Treatment, Human, Respiratory disease, Obstructive pulmonary disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0080396
Code Inist : 002B02D. Création : 199608.